Drug Profile
Insulin glargine biosimilar - Harvest Moon Pharmaceuticals
Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Harvest Moon Pharmaceuticals
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Diabetes-mellitus in Unknown (SC)
- 14 Aug 2013 Clinical trials in Diabetes mellitus (SC)